OBJECTIVE To establish the self contrast and correction factor method for the content determination of the related substances in compound ezetimibe and rosuvastatin calcium tablets simultaneously. METHODS RP-HPLC method was adopted. The determination was performed on Kromasil 100-5 C18 Dimensions column (4.6 mm×250 mm, 5 μm) with mobile phase A consisting of methanol-acetonitrile-0.05 mol·L-1 potassium dihydrogen phosphate (adjusted to pH 4.0 with phosphoric acid) (10∶30∶60) and mobile phase B consisting of tetrahydrofuran-acetonitrile-0.05 mol·L-1 potassium dihydrogen phosphate (adjusted to pH 4.0 with phosphoric acid) (10∶50∶40) at a flow rate of 1.0 mL·min-1. The detection wavelength was set at 242 nm. The injection volume was 20 μl. The slope of linear equation was used to determine the correction factors between ROS impurities 1, 2, 3, EZT impurities 1, 2, 3, 4, 5, 6, 7 and ezetimibe or rosuvastatin calcium. The relative retention time was used to determine the positions of impurities. RESULTS The relative retention time of ROS impurities 1, 2, 3, 4 and EZT impurities 1, 2, 3, 4, 5, 6, 7 to rosuvastatin calcium was 1.5, 1.9, 2.1, 1.1, 1.7, 2.5, 2.6, 2.8, 2.9, 3.0, and 4.0, respectively.The correction factors of ROS impurities 1, 2, 3, 4 and EZT impurities 1, 2, 3, 4, 5, 6, 7 were 1.1, 1.1, 1.0, 1.0, 1.3, 1.1, 1.0, 1.3, 1.4, 0.5, and 1.0,respectively.The content of ROS impurity 4 was 0.15% in three batches of samples, the other impurities were less than 0.1%, and the contents of total impurities were 0.27%, 0.27%, and 0.26%, respectively. CONCLUSION The method is simple,efficient, and accurate for analyzing the related substances in compound ezetimibe and rosuvastatin calcium tablets.
ZHU Xue-ping, CHEN Ai-ping, DAI Yun-zhi.
HPLC Method with Correction Factor for Determination of Related Substances in Compound Ezetimibe and Rosuvastatin Calcium Tablets[J]. Chinese Pharmaceutical Journal, 2017, 52(2): 140-146 https://doi.org/10.11669/cpj.2017.02.012
ZHOU Z H,ZHUANG H F,YU X,et al. Determination of related substances in ezetimibe by RP-HPLC. Chin J Exp Tradit Med Form(中国实验方剂学杂志),2013,19(19):159-162. WANG L,LI H. Determination of the content in Rosuvastatin Calcium tablets by HPLC. Chin Rem Clin (中国药物与临床), 2007,7(4):309-310. WEI P,WU Q,FU Q, et al. Effects of rosuvastatin combined with ezetimibe on plasma lipid and high sensitive C-reactive protein in acute coronary syndrome. Chin J Clin (Electronic Edition) ,2012,6(23):540-7542. Ch. P(2015) Vol Ⅴ (中国药典2010年版. 四部). 2015:60 DING L. Drug Chromatographic Analysis(药物色谱分析). Beijing:People′s Medical Publishing House,2011:286-291. YE H,ZHANG M. RP-HPLC simultaneouly determination of diclofenac sodium,misoprostol and its related impurities in compound misoprostol tablet. Chin Pharm J(中国药学杂志),2000,35(3) : 192-194.